Diabetes

A study published in BMJ measured the prevalence, annual compensation, and beneficial stock ownership of directors from publicly traded healthcare companies who had academic affiliations.

This study extends value-based insurance design concepts in testing the impact on blood pressure control of rewards that provided negative co-payments for blood pressure medication.

This study tests the impact on blood pressure control of a reward that lowered co-payments for blood pressure medication to $0.

Results presented at the American Diabetes Association in June showed no CV risk or benefit and no risk of pancreatic injury, an issue that has been of particular concern to FDA.

The recommendations for improving quality care in Medicaid track recent trends in psychiatric and diabetes care, which recognize the connection between physical and mental health.

The technology was approved by FDA in June and unveiled at the Scientific Sessions of the American Diabetes Association.

Eighty-six million US adults are at high risk of developing type 2 diabetes. Without prevention, there will be a drastic increase in the number of Americans who will develop type 2 diabetes.

Many hoped the 2013 declaration by the American Medical Association that obesity is a disease would open the door for payer coverage of pharmacotherapy to treat it. While that did not happen right way, a new commentary in Evidence-Based Diabetes Management by Ted Kyle, RPh, MBA, and Fatima Cody Stanford, MD, MPH, MPA, outlines how the tide appears to be turning for coverage of evidence-based treatment.

Peter S. Amenta, MD, PhD, spent 8 years as the dean of Rutgers Robert Wood Johnson Medical School during a period of tremendous growth and change.

The research by the group from Spain is the latest effort to link sleep patterns, or disruption of sleep, to the development of type 2 diabetes.

Fingernail tests could offer a solution to diabetes testing in the developing world, and a faster test for gestational diabetes could diagnose this condition earlier in pregnancy.

A JAMA Internal Medicine study found the terms "breakthrough" and "promising" raised people's expectations on the drug's performance as opposed to when the drugs were described as having met the breakthrough criteria.

Younger patients and those newly diagnosed were more likely to not receive eye exams than older persons with diabetes.

Screening in a primary care setting may help managed care plans avoid long-term costs of complications of type 2 diabetes.

Hillary Clinton unveiled a plan in Iowa that features a $250 per month cap on drug costs for patients with chronic conditions. This comes 2 weeks after her chief rival for the Democratic nomination, US Senator Bernie Sanders of Vermont, introduced a bill aimed at reining in drug costs. In the summer, The American Journal of Managed Care said polling showed that rising drug costs were poised to become a major issue in the 2016 campaign.

A white paper released by QuantiaMD has identified a lack of awareness and education about biosimilars among prescribing physicians.

The matchstick-like delivery system has been seen as game-changer in overcoming poor adherence. Filing for FDA approval is anticipated in early 2016.

The study showed an average weight loss of 6%, and weight loss of 10% for a quarter of the patients. Average BMI was 37.

The research could hold the key to a novel treatment for type 2 diabetes, although it will take years to adapt the idea to clinical practice.

Researcher found that not only was passive smoking associated with increased risk of type 2 diabete, but there was a direct dose-response relationship.

A report in The New York Times identifies challenges that could be raised based on Califf's past associations with the drug industry.

Although primary care is important, it may not be the center of the care model for patients with chronic diseases, like type 2 diabetes, and these providers are usually just a part of a larger ecosystem of providers, said Andrew Pumerantz, DO, FACP.